GATA2 Deficiency — Comprehensive Research Report

(Prepared for dismech curation. Per project convention, germline predisposition is treated separately from the somatic myeloid malignancies it predisposes to — see §6 and the note in §2. Basic genetics concepts (penetrance, mosaicism, haploinsufficiency mechanics) are not re-explained here per user context; the report leads with disease-specific claims and citations.)

1. Disease Information

Overview. GATA2 deficiency (GATA2 deficiency syndrome, G2DS) is an autosomal dominant disorder caused by heterozygous germline pathogenic variants in GATA2, a master hematopoietic zinc-finger transcription factor. A single genetic lesion produces a syndrome that was originally described as four apparently separate entities before their shared molecular cause was recognized: MonoMAC syndrome (monocytopenia with Mycobacterium avium complex infection), DCML deficiency (dendritic cell, monocyte, B- and NK-lymphoid deficiency), Emberger syndrome (primary lymphedema with MDS), and familial MDS/AML. Spinner et al. (Blood 2014, PMID:24227816) established that these are one disorder: "Haploinsufficiency of the hematopoietic transcription factor GATA2 underlies monocytopenia and mycobacterial infections; dendritic cell, monocyte, B, and natural killer (NK) lymphoid deficiency; familial myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML); and Emberger syndrome." This is a curatorial lump call already made in the field — current nomenclature (Calvo & Hickstein, Blood 2023;141(13):1524–1532, PMID:36455197, "The spectrum of GATA2 deficiency syndrome") treats MonoMAC/DCML/Emberger/familial MDS-AML as phenotypic variation on one genetic lesion rather than genuinely distinct diseases, which should be reflected as has_subtypes or historical-synonym framing rather than separate dismech entries.

Key identifiers: - Gene: GATA2, HGNC:4173, OMIM 137295, chromosome 3q21.3 - OMIM phenotypes: Immunodeficiency 21 (MonoMAC) #614172; Emberger syndrome #614038; MDS predisposition (germline GATA2 mutation) #614286; AML predisposition citing GATA2 under #601626 - MONDO: MONDO:0013607 (GATA2 deficiency) - Orphanet: ORPHA:228423 (GATA2 deficiency spectrum) - ICD-10: D72.8 (other specified disorders of white blood cells) — no dedicated ICD-10/11 code exists - MeSH:* overlapping entries under primary immunodeficiency/MDS headings; no single dedicated MeSH descriptor

Synonyms: MonoMAC syndrome; DCML deficiency; Emberger syndrome; familial MDS/AML with GATA2 mutation; NK cell deficiency (GATA2-related); MGN syndrome (monocytopenia and mycobacterial infection).

Evidence base: Predominantly aggregated disease-level cohort data — the NIH natural history cohort (Spinner 2014, n=57, PMID:24227816), a French/Belgian multicenter cohort of 79 patients (Haematologica), and registry-based pediatric HSCT series (EWOG-MDS, n=65) — supplemented by individual case reports for rarer manifestations (interstitial lung disease, Hodgkin lymphoma). This is not primarily an EHR-derived phenotype.

2. Etiology

Disease causal factor: Monogenic. Heterozygous germline pathogenic GATA2 variants are necessary and sufficient; there is no reported environmental or infectious primary cause. (Note the important genocopy distinction for dismech: somatic 3q26/MECOM rearrangements — inv(3)(q21q26), t(3;3)(q21;q26) — hijack the distal GATA2 hematopoietic enhancer (G2DHE) to drive EVI1 overexpression while silencing GATA2 on the rearranged allele in sporadic AML; this is a somatic leukemia mechanism that convergently reduces GATA2 dosage and should NOT be modeled as the same pathophysiology node as germline GATA2 deficiency, even though both produce "GATA2 haploinsufficiency" biochemically. (Atlas Genet Cytogenet Oncol Haematol; Blood 2020;136(2):224, "Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia.")

Genetic risk factors: - ~50% de novo variants; remainder inherited from an affected or (rarely) mosaic/asymptomatic parent (Homan et al., Hum Mutat 2021, PMID:34387894, "GATA2 deficiency syndrome: A decade of discovery" — confirms de novo variants in "24 individuals... among over 480 individuals with germline GATA2 pathogenic or likely pathogenic variants" in the aggregate literature). - Variant classes: (1) missense variants clustering in the C-terminal zinc finger (ZF2) DNA-binding domain, notably the recurrent hotspot R396Q; (2) null variants (nonsense, frameshift, splice-site, whole-gene deletion); (3) ~10% noncoding variants disrupting the intron-4 −77/+9.5-equivalent human enhancer (the "EBOX-GATA-ETS" element) or the distal hematopoietic enhancer region, causing regulatory haploinsufficiency without coding change (PDQ GATA2 Deficiency Syndrome, NCBI Bookshelf NBK606140). - No pathogenic GATA2 variants are present in gnomAD population databases, consistent with high penetrance and reproductive/somatic selection against germline carriage in the general population. - Genotype-phenotype correlation: null variants associate more strongly with viral infection susceptibility and lymphedema than missense variants (Spinner 2014, PMID:24227816); the PDQ summary states lymphedema specifically "is associated with GATA2 null pathogenic variants."

Modifier/susceptibility factors — somatic events, not germline risk factors: Progression to MDS/AML is driven by acquired somatic lesions superimposed on the germline haploinsufficient marrow: monosomy 7 (70–80% of pediatric MDS cases, 20–40% of adult cases), trisomy 8 (20–40% of adults), der(1;7) translocation, and somatic mutations in ASXL1, STAG2, SETBP1, and RUNX1. STAG2 mutation frequency and trisomy 8 both increase with age (PDQ summary; Blood 2023 review).

Protective factors: None specific to germline variant type are established. No population-level protective allele has been reported (consistent with gnomAD absence of the pathogenic alleles).

Environmental risk modifiers / gene-environment interaction: Not a primary environmental disease. The immunodeficiency component determines which pathogens cause disease (nontuberculous mycobacteria, HPV, EBV, fungi) rather than environmental exposure causing the underlying lesion — this is host-susceptibility, not classic gene-environment interaction.

3. Phenotypes

Frequencies below are from the NIH cohort (Spinner et al., Blood 2014, n=57, PMID:24227816) unless noted; onset/course descriptors are qualitative syntheses from the same source and the 2023 Blood review.

Onset/course: Median age of clinical onset ~18–20 years (range 0–78), with the constellation typically emerging in late childhood through early adulthood rather than infancy — pediatric presentation is usually cytopenia/MDS or infection-driven rather than the constitutional (deafness/lymphedema) features, which are congenital but often noted retrospectively. Median age of myeloid neoplasm diagnosis is bimodal — ~12 years in pediatric-onset disease vs. ~35 years in adult-onset (PDQ NBK606140) — a distinction directly relevant to the dismech pediatric-framing convention: pediatric GATA2-MDS is disproportionately monosomy-7-driven (70–80% vs. 20–40% in adults) and behaves as a more aggressive, faster-progressing entity than adult-onset GATA2-MDS, arguing for treating pediatric vs. adult progression as distinguishable progression phases rather than a single undifferentiated course. Course is progressive and highly variable in tempo, even within families sharing an identical variant — some carriers remain asymptomatic lifelong. Lifetime penetrance is estimated at >80% by age 60 across the aggregate literature (~90% cited in some cohorts).

Quality of life: Not separately quantified with EQ-5D/SF-36 instruments in the literature identified; QoL burden is described narratively (chronic infection burden, HSCT-related morbidity, malignancy anxiety) rather than measured with standardized instruments.

4. Genetic/Molecular Information

Causal gene: GATA2 (HGNC:4173, NCBI Gene 2624, OMIM *137295), chromosome 3q21.3. Six zinc-finger-transcription-factor exons; two zinc fingers (ZF1 N-terminal, ZF2 C-terminal DNA-binding).

Variant classification and type: - Missense — the single largest reported class; in one series "19 different missense mutations were identified in 24 probands and 14 relatives (46%)." Cluster predominantly in ZF2. Recurrent hotspot p.R396Q is the subject of a dedicated 2024/2025 knock-in mouse model (below). - Null variants — nonsense, frameshift, canonical splice-site, whole-gene deletion, and even some synonymous variants shown to disrupt splicing. - Regulatory/noncoding — ~10% of cases: point substitutions or small indels in the intron-4 enhancer element (variously termed the −77/G2DHE/"EBOX-GATA-ETS" enhancer, human ortholog of the mouse +9.5 kb enhancer), and tandem duplications. - Functional impact category: predominantly loss-of-function / haploinsufficiency; ZF2 missense variants can also act as partial loss-of-function or, in some reports, weakly dominant-negative on DNA binding, but there is no established gain-of-function class in the germline deficiency syndrome (contrast with somatic GATA2 zinc-finger mutations reported in a minority of AML, which is a distinct oncogenic context, not germline deficiency).

Population frequency: Pathogenic GATA2 variants are absent from gnomAD — consistent with high penetrance for severe, reproductively/medically consequential disease and largely de novo/small-pedigree transmission rather than population-level carrier frequency.

Somatic (acquired) lesions on the germline background — the genetic path to MDS/AML: - Monosomy 7: 70–80% of pediatric GATA2-MDS; 20–40% of adult cases; in the original NIH cohort 16% had monosomy 7 and 24% trisomy 8 at any point, rising with disease evolution. - der(1;7) unbalanced translocation. - Somatic driver mutations: ASXL1, STAG2, SETBP1, RUNX1 (STAG2 and trisomy 8 frequency increase with age). - Clinical decision rule with direct diagnostic utility: "up to 72% of adolescents with an MDS diagnosis and monosomy 7 carry germline GATA2 pathogenic variants" (PDQ NBK606140) — monosomy-7 pediatric MDS should trigger germline GATA2 testing.

Distinguish from somatic 3q26/MECOM AML (see §2): In sporadic inv(3)/t(3;3) AML, a cis enhancer-hijacking event silences GATA2 on one allele while activating MECOM (EVI1) — mechanistically convergent on GATA2 haploinsufficiency but a different disease with a different genetic architecture (somatic structural rearrangement, no germline predisposition, distinct prognosis) and should not be curated under the germline GATA2 deficiency entry.

Epigenetics: A 2024 preprint/2025 published mechanistic study (PMID:38887897, "GATA2 heterozygosity causes an epigenetic feedback mechanism resulting in myeloid and erythroid dysplasia") proposes that GATA2 haploinsufficiency triggers a self-reinforcing epigenetic state (histone trimethylation changes reported in pediatric MDS marrow, PMC10705137) that entrenches dysplastic differentiation independent of additional mutation — relevant to modeling a biological_scale: MOLECULAR epigenetic node upstream of the cellular dysplasia node.

Chromosomal abnormalities: Not a primary chromosomal disorder; the relevant chromosomal abnormalities (monosomy 7, trisomy 8, der(1;7)) are all acquired somatic events in evolving marrow, not constitutional karyotype anomalies.

5. Environmental Information

GATA2 deficiency has no established environmental, dietary, or lifestyle causal factor — this is a purely monogenic host-susceptibility disorder. The "environmental" dimension of the disease is instead about which pathogens the immunodeficiency renders the host susceptible to, i.e., infectious triggers acting on a genetically primed innate/adaptive immune defect rather than independent causal exposures:

• Nontuberculous mycobacteria (M. avium complex predominantly, also M. kansasii — PMC6489290 case report) — the defining infection of "MonoMAC."
• Human papillomavirus — extensive cutaneous and anogenital disease, with malignant transformation risk (35% HPV-positive tumors).
• Epstein-Barr virus — EBV-driven lymphoproliferative disease and reported Hodgkin lymphoma (PMC12719254, case report of siblings).
• Herpesviruses (HSV, VZV) and disseminated fungal pathogens (Histoplasma capsulatum specifically implicated given the monocyte/macrophage defect).

No occupational, toxin, radiation, or dietary exposure is reported as a disease modifier in the identified literature; this section should largely be left unpopulated in a KB entry beyond the infectious-trigger framing above (which functionally belongs with the phenotype/pathophysiology sections as infection-driven complications of the immunodeficiency, not environmental[] causal exposures in the dismech schema sense).

6. Mechanism / Pathophysiology

Ordered causal chain

1. A heterozygous germline GATA2 pathogenic variant (coding loss-of-function, ZF2 missense, or enhancer disruption) leads to ~50% reduction in functional GATA2 transcription-factor dosage in hematopoietic stem and progenitor cells (HSPCs) — GATA2 haploinsufficiency.
2. Reduced GATA2 dosage disrupts the GATA2–FLI1–TAL1/SCL recursive regulatory triad and downstream target activation (e.g., HOXB4), which normally governs HSC specification, quiescence, and self-renewal — this results in impaired HSC homeostasis: aged/stressed Gata2-haploinsufficient HSCs show reduced self-renewal capacity and a myeloid-biased, proliferative shift rather than maintained quiescence (Blood Advances 2021, PMID pending verification; Gata2 haploinsufficiency mouse studies).
3. Loss of the stem-cell "gatekeeper" function leads to a preleukemic state: single-cell transcriptomic studies of patient HSPCs (Blood Advances, "Sequencing of RNA in single cells...") show dysregulated apoptosis/cell-cycle/quiescence genes, increased erythroid/megakaryocytic priming, and decreased lymphoid priming — an early, cell-intrinsic bias toward the myeloid-dysplastic phenotype before any acquired somatic mutation.
4. Concurrently, GATA2 haploinsufficiency in non-stem lineages results in disproportionate, near-complete loss of monocytes, B-cell precursors, NK cells, and circulating/tissue dendritic cells, with relative sparing of T cells — this is a lineage-selective, dosage-sensitive effect rather than pan-hematopoietic failure, consistent with GATA2's role in "activating pro-fate targets... in granulocyte-macrophage progenitors and... repressing alternative-fate genes... in dendritic-cell progenitors."
5. The monocyte/dendritic-cell/NK deficiency leads to the clinical immunodeficiency phenotype: susceptibility to nontuberculous mycobacteria and Histoplasma (intramacrophagic pathogens, reflecting monocyte/macrophage dysfunction), HPV (reflecting NK/DC-mediated antiviral surveillance loss), and EBV/herpesvirus disease.
6. In the lung, insufficient monocyte-derived alveolar macrophage reconstitution results in defective pulmonary surfactant clearance, manifesting as pulmonary alveolar proteinosis and diffusion/ventilatory defects — mechanistically analogous to (but genetically distinct from) CSF2RA-related hereditary PAP, since here the defect is upstream monocyte/macrophage supply rather than GM-CSF receptor signaling itself.
7. Independently, in lymphatic endothelial cells, GATA2 haploinsufficiency disrupts direct transcriptional activation of PROX1 and FOXC2 (GATA2 binds regulatory elements in the PROX1 promoter) and of the GATA2 target miR-126, which is required for VE-cadherin/claudin-5 junctional integrity — this leads to dysmorphic, incompetent lymphatic and lymphovenous valves, producing the lymphedema phenotype in a subset (more penetrant with null variants) (PMC6857586, "GATA2 controls lymphatic endothelial cell junctional integrity and lymphovenous valve morphogenesis through miR-126"; Blood 2012;119(5):1283, original description of lymphedema-MDS GATA2 link).
8. Over years, the haploinsufficient, epigenetically primed marrow acquires somatic second hits — most consequentially monosomy 7, but also trisomy 8, der(1;7), and mutations in ASXL1/STAG2/SETBP1/RUNX1 — which result in clonal evolution to myelodysplastic syndrome and, in a subset, transformation to AML or CMML. This step is the somatic-mutation-driven branch and is the appropriate place for a conforms_to link to a myeloid-malignancy/clonal-evolution module rather than modeling AML as germline-caused per se.
9. Branch: in a minority, chronic marrow failure and dysplasia proceed to bone marrow failure independent of overt leukemic transformation, distinguishable histologically from idiopathic aplastic anemia by hypocellularity with reticulin fibrosis and atypical megakaryocytes in 92% of marrows (Blood 2015;125(1):56, "GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia").

Molecular pathways

GATA2 operates in a recursively autoregulated triad with FLI1 and TAL1/SCL, each binding the others' enhancers, at the apex of the HSC transcriptional network; it acts upstream of RUNX1 via the +23 enhancer (GATA2/FLI1/SCL complex assembly) and directly transactivates HOXB4. GO terms: GO:0030099 (myeloid cell differentiation), GO:0002520 (immune system development), GO:0060716 (labyrinthine layer blood vessel development – lymphatic analog), GO:0001945 (lymph vessel development).

Cellular processes and cell types

Affected cell types (CL terms): hematopoietic stem cell (CL:0000037), common myeloid progenitor, monocyte (CL:0000576), classical/plasmacytoid dendritic cell (CL:0000451/CL:0000784), natural killer cell (CL:0000623), B lymphocyte precursor (CL:0000816), alveolar macrophage (CL:0000583), lymphatic endothelial cell (CL:0002138).

Protein dysfunction

Predominantly loss-of-function at the protein level (reduced/absent functional protein from the mutant allele, or reduced transcription from a disrupted enhancer) rather than protein misfolding/aggregation. ZF2 missense variants impair sequence-specific DNA binding at GATA motifs without necessarily eliminating protein expression.

Advanced/omics findings (2023–2025)

• Single-cell transcriptomics of patient HSPCs shows constrained gene correlation networks and myeloid-biased priming preceding overt MDS (Blood Advances, cited above).
• A 2024/2025 Gata2^R396Q/+ knock-in mouse (Leukemia, 2024, "Modeling GATA2 deficiency in mice") recapitulates HSC functional decline, lineage-fate bias, and an accelerated-aging transcriptional signature in HSPCs, but — notably — does not spontaneously develop marked immunodeficiency or MDS/AML, indicating the germline lesion alone is necessary but not sufficient and that additional (likely somatic) drivers are required for full disease. This is directly relevant to a dismech HUMAN_MODEL_MISMATCH discussion: the mouse model recapitulates the preleukemic HSC phenotype (RECAPITULATES, MODERATE fidelity) but FAILS_TO_RECAPITULATE the leukemic/immunodeficiency endpoints.
• A 2025 CRISPR-engineered isogenic human HSPC model (Leukemia, "CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs") shows mitotic dysfunction and premature cellular aging as a proximate mechanism linking haploinsufficiency to HSC exhaustion — an IN_VITRO-graded mechanistic link.
• A 2025 study (Blood Cancer Journal, "GATA2 mutated allele specific expression is associated with a hyporesponsive state of HSC") reports allele-specific expression skewing toward the mutant allele in some patients, correlating with an HSC hyporesponsive/exhausted state — a genotype-severity modifier worth flagging as a mechanistic_hypotheses candidate (status: EMERGING) rather than established.

7. Anatomical Structures Affected

• Organ/system level: Bone marrow/hematopoietic system (primary); immune system (monocyte/DC/NK/B compartments); lymphatic vasculature; lung (parenchyma/alveolar macrophage compartment); inner ear (cochlea, sensorineural); reproductive/urogenital system (miscarriage, urogenital malformation); thyroid (hypothyroidism); skin (warts, panniculitis); vascular system (venous thrombosis).
• UBERON suggestions: bone marrow (UBERON:0002371), lymphatic vessel (UBERON:0001473), lymphovenous valve region, lung alveolus (UBERON:0002299), cochlea (UBERON:0000132), thyroid gland (UBERON:0002046).
• Tissue/cell level: hematopoietic stem/progenitor compartment (bone marrow niche), lymphatic endothelium (valve-forming LECs specifically), alveolar macrophage/type II pneumocyte-adjacent monocyte-derived population, cochlear sensory epithelium (mechanism not detailed in identified literature — noted gap).
• Subcellular: GO Cellular Component — nucleus (site of GATA2 transcriptional activity, GO:0005634); mitochondria implicated in the "increased mitochondrial mass/activity" preleukemic transition described above.
• Localization/laterality: Lymphedema and hearing loss are typically bilateral; no lateralization pattern reported.

8. Temporal Development

• Onset: Constitutional features (congenital sensorineural deafness, lymphedema when present, urogenital anomalies) are present from birth/early childhood but often recognized only retrospectively after a hematologic/infectious diagnosis. Symptomatic hematologic/immunologic disease has a median clinical onset ~18–20 years, with a bimodal split: pediatric-onset myeloid neoplasm (median age ~12) skews toward monosomy-7-driven, more aggressive MDS, while adult-onset disease (median age ~35) has a broader genetic and clinical spectrum.
• Progression: Chronic, generally progressive — cytopenias evolve toward dysplasia, then MDS, with a subset transforming to AML/CMML. Course is highly variable in tempo, including intrafamilial variability among carriers of an identical variant; some remain lifelong asymptomatic (partial/incomplete penetrance).
• Disease stages: Refractory cytopenia of childhood (RCC) → MDS with excess blasts → AML, tracked with standard pediatric/adult MDS staging (WHO/EWOG-MDS criteria) rather than a GATA2-specific staging system; monosomy-7 status is the dominant prognostic stratifier at each stage.
• Remission/critical periods: No spontaneous remission pattern reported for the hematologic component; HSCT is the only means of durable remission/cure (see §12). The "critical period" for intervention is framed clinically as before irreversible organ damage (established pulmonary fibrosis/PAP, advanced MDS/monosomy 7) — i.e., earlier HSCT in patients with RCC and normal karyotype yields markedly better outcomes than delayed transplant after monosomy-7 evolution.

9. Inheritance and Population

• Epidemiology: GATA2 deficiency accounts for ~7% of pediatric MDS and ~0.5% of adult MDS (PDQ NBK606140) — making it one of the most common single-gene predispositions to pediatric MDS specifically, though the disorder overall remains ultra-rare in the general population (no pathogenic alleles present in gnomAD).
• Inheritance pattern: Autosomal dominant, de novo in roughly half of probands, otherwise inherited from an affected (or occasionally minimally symptomatic) parent.
• Penetrance: Estimated >80% by age 60 in aggregate cohorts (some series cite ~90%); notably incomplete and age-dependent — a meaningful fraction of adult carriers remain hematologically/immunologically asymptomatic well into adulthood, which is directly relevant to genetic-counseling framing for asymptomatic relatives identified by cascade testing.
• Expressivity: Markedly variable, including within families sharing an identical variant — siblings/parent-child pairs with the same mutation can present decades apart or with different organ-system emphasis (hematologic vs. lymphatic vs. pulmonary).
• Germline mosaicism / founder effects: Not prominently reported as a recurring theme in the literature identified (most non-inherited cases are simple de novo, not parental mosaicism); no specific population founder variant has been described — pathogenic variants are private/family-specific, consistent with absence from gnomAD.
• Consanguinity: Not implicated (autosomal dominant, not recessive).
• Population demographics: No strong reported ethnic/geographic enrichment; case series are drawn from North American and European cohorts (NIH, French/Belgian) without a described differential prevalence by ancestry. Sex ratio is not reported as skewed; reproductive-age women show a notably high miscarriage rate (33%), relevant to counseling but not to differential incidence by sex.

10. Diagnostics

Genetic testing: - First-line: targeted GATA2 sequencing (including intron-4 enhancer region and copy-number analysis for whole-gene deletion) via NGS full-gene panels (e.g., Mayo Clinic Labs "GATAS" full gene analysis) — germline confirmation requires testing a non-hematopoietic tissue (cultured skin fibroblasts) when a hematologic malignancy is already present, to distinguish germline from somatic GATA2 involvement, and parental testing to establish de novo status. - Diagnostic trigger rule: monosomy 7 in a young MDS patient should prompt germline GATA2 testing (up to 72% of monosomy-7 pediatric MDS carries a germline GATA2 variant). - Testing is also indicated for family members being evaluated as potential HSCT donors, given the risk of transplanting a mutation-carrying graft (see §12).

Laboratory/immunophenotyping: Peripheral blood flow cytometry showing profound monocytopenia, B-lymphopenia, NK-lymphopenia, and dendritic cell deficiency with relative T-cell preservation and inverted CD4:CD8 ratio is a strong clinical pattern-recognition diagnostic clue predating genetic confirmation.

Bone marrow evaluation: Hypocellular marrow with reticulin fibrosis and atypical megakaryocytes (92% of cases) distinguishes GATA2-associated marrow failure from idiopathic aplastic anemia; cytogenetics (monosomy 7, trisomy 8) and somatic NGS panel (ASXL1, STAG2, SETBP1, RUNX1) for clonal evolution monitoring.

Imaging/functional testing: Pulmonary function testing (DLCO, spirometry) for the diffusion/ventilatory defects seen in the majority of patients; high-resolution CT for PAP or interstitial lung disease (a 2025 case report series documents "early-onset and progressive interstitial lung disease" as a GATA2 presentation, PMC12012643).

Differential diagnosis: Other inherited bone marrow failure/MDS-predisposition syndromes should be excluded or co-considered — SAMD9/SAMD9L syndromes, RUNX1 familial platelet disorder, ANKRD26-related thrombocytopenia, DDX41-related MDS/AML, SRP72-related BMF, telomere biology disorders (dyskeratosis congenita), Fanconi anemia, and ELANE-related severe congenital neutropenia — each has a distinct genetic/phenotypic signature but overlapping marrow-failure presentation.

Screening (established carriers): Periodic CBC/immune-status monitoring; yearly bone marrow evaluation with cytogenetics and somatic variant testing; HPV-related cancer screening (cervical/anal); avoidance of G-CSF (theoretical clonal-evolution risk).

11. Outcome/Prognosis

Malignancy risk: 75–80% lifetime risk of developing myeloid malignancy among symptomatic carriers; "80% of patients aged 40 having developed MDS/AML" in some cohort framings. MDS is the first hematologic diagnosis in 75% of malignancy cases, with AML developing in a further ~9–14% and CMML in ~8%.

Survival without treatment: Not separately quantified as an untreated natural-history survival curve in the identified literature (nearly all symptomatic patients proceed to HSCT); mortality risk is driven by both infectious complications (disseminated NTM, invasive fungal disease) pre-transplant and by malignant transformation.

Prognostic stratifiers: Karyotype at the time of transplant is the dominant prognostic factor — refractory cytopenia of childhood (RCC) with a normal karyotype carries excellent HSCT outcomes (DFS ~90%), while RCC with monosomy 7 is markedly worse (DFS ~67%); advanced MDS/AML at transplant and monosomy 7 both independently associate with worse post-HSCT outcome.

HSCT outcomes (pooled/registry data): - EWOG-MDS pediatric registry (n=65 with germline GATA2 mutation): 5-year overall survival 75%, disease-free survival 70%; treatment failure attributable roughly equally to non-relapse mortality and relapse (Bone Marrow Transplantation 2021, PMC8563415). - French/Belgian adult+pediatric series (n=67): long-term outcome analysis (British Journal of Haematology, cited above) — outcomes vary by disease stage at transplant, consistent with the karyotype-stratified pattern above. - Reported adult overall survival figures by indication in the PDQ synthesis: 54% (MDS/AML or immunodeficiency, general), 66% (children, MDS, monosomy 7), 88% (children, RCC, normal karyotype), 86% (young adults, immunodeficiency-predominant indication).

Complications: Chronic infection burden pre-transplant (NTM, fungal, HPV-driven neoplasia), post-HSCT graft-versus-host disease (not reported as increased over baseline in this population), and the specific transplant-related hazard of donor-derived MDS/AML when a related donor is an unrecognized mutation carrier — underscoring the requirement for donor germline testing in familial transplant.

Recovery potential: Successful HSCT reverses the cellular immunodeficiency phenotype (monocyte/B/NK reconstitution), resolves infection susceptibility, and eliminates the ongoing risk of leukemic transformation from the native marrow — i.e., HSCT is curative for the hematologic/immunologic disease, though it does not reverse pre-existing structural organ damage (established lymphedema, pulmonary fibrosis) accrued before transplant, which is the rationale for early referral.

12. Treatment

Curative therapy: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment and is recommended for essentially all symptomatic patients — nearly all individuals with GATA2-related MDS eventually undergo HSCT. NCIT: NCIT:C15431 (Hematopoietic Cell Transplantation) as therapeutic_modality: CELL_THERAPY. - Timing: should occur before irreversible organ damage — i.e., before advanced MDS/monosomy-7 evolution and before established pulmonary or lymphatic structural damage, given the strong karyotype-at-transplant prognostic effect described in §11. - Indications: recurrent infections, transfusion dependency, or clonal evolution to myeloid malignancy. - Conditioning: individually tailored; both myeloablative and reduced-intensity/nonmyeloablative regimens have been reported (a busulfan-based regimen is specifically described in one series, PMID:29412158); a 2025 registered trial (NCT05907746) is evaluating briquilimab (anti-CD117 antibody)–based conditioning as a lower-toxicity alternative — relevant as an emerging/experimental regimen. - Donor selection caveat: mandatory germline GATA2 testing of related potential donors, given reported donor-derived MDS/AML when an unrecognized carrier relative was used as donor.

Pharmacotherapy / supportive care: - Prophylactic azithromycin (empiric, for NTM prevention) — CHEBI azithromycin; treatment_term: NCIT:C15986 Pharmacotherapy, therapeutic_agent: azithromycin. - Antifungal prophylaxis in patients with severe cellular immunodeficiency. - Interferon-alfa has in vitro/small-series support for improving NK-cell cytotoxicity, considered for refractory HPV or herpesvirus disease. - HPV vaccination is empirically recommended early, given the marked HPV susceptibility (NCIT:C15346 Vaccination). - G-CSF is avoided due to theoretical clonal-evolution risk in a genetically primed marrow.

Experimental/advanced therapeutics (2025): - CRISPR-Cas9 allele-specific gene correction in autologous HSPCs using rAAV6-mediated homology-directed repair has been reported as a proof-of-concept therapeutic strategy (Molecular Therapy, 2025, PMID:40739756) — positions autologous gene-corrected HSCT as a prospective alternative to allogeneic transplant, avoiding GVHD/donor-search barriers; still preclinical/early-phase, not standard of care. - Briquilimab-conditioned HSCT trial (NCT05907746), ongoing.

No consensus clinical practice guideline yet exists for GATA2 deficiency management — surveillance and treatment intensity remain individually tailored, per the 2023 Blood review and the PMC10000430 clinical-spectrum review.

13. Prevention

• Primary prevention: Not applicable to the germline lesion itself (no modifiable risk factor); HPV vaccination functions as primary prevention against the downstream HPV-driven malignancy risk specifically.
• Secondary prevention/screening: Structured surveillance in known carriers — periodic CBC/immune monitoring, annual bone marrow evaluation with cytogenetics/NGS for clonal evolution, HPV-related cancer screening (cervical/anal cytology) — functions as early detection of transformation to enable earlier, better-outcome HSCT.
• Genetic counseling: Autosomal dominant inheritance with incomplete, age-dependent penetrance and highly variable expressivity should be explicitly communicated to families — an asymptomatic parent may still be a carrier, and cascade testing of first-degree relatives (including potential HSCT donors) is clinically actionable. No formal prenatal/preimplantation genetic testing protocol specific to GATA2 was identified in the literature searched, though the general NGS-based testing infrastructure (used for other monogenic PGT indications) is technically applicable; this should be flagged as an inferred extrapolation, not a documented GATA2-specific practice.
• Prophylaxis: Azithromycin (NTM) and antifungal prophylaxis in immunodeficient carriers function as tertiary/complication prevention rather than disease prevention per se.
• Public health: No population screening program exists (ultra-rare, gnomAD-absent alleles); this is managed entirely through clinical/familial ascertainment, not newborn or population screening.

14. Other Species / Natural Disease

No naturally occurring GATA2-deficiency-like disease has been identified in this search in companion animals, livestock, or wildlife (no OMIA entry or veterinary case series located) — this section should record an explicit "not found" rather than a fabricated cross-species claim. This is consistent with the pattern that most engineered animal work on GATA2 is laboratory-model-driven (mouse, zebrafish) rather than a naturally arising veterinary phenocopy.

Orthology: Gata2 is highly conserved; mouse ortholog Gata2 (MGI:95662), zebrafish has two paralogs gata2a and gata2b (from a teleost genome duplication) with partially divergent functions (see §15).

15. Model Organisms

• Mouse — full knockout: Gata2-null mice are embryonic lethal at E10.5 due to failure of definitive hematopoiesis, establishing GATA2 as essential (not merely modulatory) for HSC generation — this is a full-null lethality that cannot model the human heterozygous-viable disease directly.
• Mouse — heterozygous/haploinsufficient models: Gata2^+/− and conditional (Vav-Cre;Gata2^fl/+) mice are viable and recapitulate HSC functional decline under proliferative/aging stress — reduced self-renewal, myeloid bias, and (in a 2025 Blood Advances study) leukemia arising specifically in the context of bone marrow failure with somatic aberrations, increased Myc-target expression, and genomic instability (PMID:40138552) — a RECAPITULATES/MODERATE-to-HIGH fidelity model for the preleukemic HSC phenotype specifically.
• Mouse — Gata2^R396Q/+ knock-in (patient-hotspot variant): recapitulates aberrant lineage-fate decisions and an accelerated-HSC-aging transcriptional signature but does not spontaneously develop marked immunodeficiency or MDS/AML — explicitly noted by the authors as requiring "additional drivers" for full disease (Leukemia, 2024). This is a clean HUMAN_MODEL_MISMATCH candidate: model recapitulates the HSC-intrinsic lesion but fails to recapitulate the clinical leukemic/immunodeficient endpoint, implying non-cell-intrinsic or additional-somatic-hit requirements not yet captured by the germline mutation alone.
• +9.5 enhancer mouse models: Deletion/mutation of the conserved Gata2 +9.5 kb enhancer disrupts adult HSC self-renewal and T-cell differentiation, modeling the human noncoding-enhancer-variant patient subset specifically (as opposed to coding variants).
• Zebrafish: Two paralogs, gata2a and gata2b; gata2b is specifically required for hematopoietic stem/progenitor cell emergence from hemogenic endothelium. Complete loss of gata2b is nonlethal (unlike mouse full knockout) and produces neutropenia, making zebrafish a genetically tractable system for adult/definitive hematopoiesis phenotyping that mouse full-knockout lethality precludes. A dedicated zebrafish MonoMAC model (bioRxiv, "A zebrafish model for MonoMAC syndrome") identifies an earlier developmental role for gata2 in hemogenic-endothelium programming than previously appreciated in mammalian systems — a fidelity caveat, since this developmental-window emphasis may not map directly onto human postnatal-onset disease.
• Human iPSC/CRISPR-engineered isogenic HSPC models (2025): Allele-specific CRISPR-Cas9 correction and CRISPR-engineered heterozygous-knockout human HSPC models directly recapitulate mitotic dysfunction and premature cellular aging (Leukemia, 2025) — the highest-fidelity in vitro human model currently reported, though still IN_VITRO rather than whole-organism.

Limitations across models: No model to date spontaneously reproduces the full human triad of (1) selective monocyte/DC/NK/B lymphoid deficiency, (2) lymphatic valve/lymphedema phenotype, and (3) progression to overt MDS/AML from a single germline lesion without additional engineered somatic hits — each model system captures a subset (HSC-intrinsic aging/exhaustion in mouse/human HSPC models; hemogenic-endothelium/HSPC-emergence biology in zebrafish; lymphatic valve morphogenesis in Gata2-conditional lymphatic-endothelial-specific mouse deletion) rather than the integrated clinical syndrome.

Summary of Suggested Ontology Bindings

Key Sources

• Spinner MA, et al. "GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity." Blood. 2014;123(6):809–821. PMID:24227816.
• Calvo KR, Hickstein DD. "The spectrum of GATA2 deficiency syndrome." Blood. 2023;141(13):1524–1532. PMID:36455197.
• Homan CC, et al. "GATA2 deficiency syndrome: A decade of discovery." Hum Mutat. 2021. PMID:34387894.
• GATA2 Deficiency Syndrome (PDQ®) — NCI/PDQ Cancer Information Summaries, NCBI Bookshelf NBK606140.
• "GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia." Blood. 2015;125(1):56.
• "Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema..." Blood. 2012;119(5):1283.
• Hematopoietic stem cell transplantation in children and adolescents with GATA2-related MDS (EWOG-MDS registry). Bone Marrow Transplant. 2021. PMC8563415.
• "GATA2 controls lymphatic endothelial cell junctional integrity and lymphovenous valve morphogenesis through miR-126." PMC6857586.
• Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in AML. Blood. 2020;136(2):224.
• "Modeling GATA2 deficiency in mice: the R396Q mutation disrupts normal hematopoiesis." Leukemia. 2024.
• "CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs." Leukemia. 2025.
• "Treatment of GATA2 deficiency by allele-specific CRISPR-Cas9-directed gene correction in hematopoietic stem cells." Molecular Therapy. 2025. PMID:40739756.
• "Hematological phenotypes in GATA2 deficiency syndrome arise from aging, maladaptation to proliferation, and somatic events." Blood Advances. 2025. PMID:40138552.
• "GATA2 mutated allele specific expression is associated with a hyporesponsive state of HSC in GATA2 deficiency syndrome." Blood Cancer J. 2025.
• OMIM #614172 (Immunodeficiency 21/MonoMAC), #614038 (Emberger syndrome), #614286 (MDS predisposition), *137295 (GATA2).
• Orphanet ORPHA:228423; MONDO:0013607.

Note on verification status: Several PMIDs above were confirmed directly from PubMed search-result metadata; article content for OMIM entries and some full-text sources could not be directly fetched (403/404 responses) and their content here is reconstructed from search-result snippets — treat OMIM clinical-synopsis details as leads requiring direct OMIM confirmation before use in a KB evidence snippet, per dismech's exact-quote requirement.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0032223 (1 mention) - the report calls it "CMML term if bound; else NCIT"; HP calls it Blood group
• HP:0032101 (1 mention) - the report calls it "Recurrent atypical mycobacterial infections, if available"; HP calls it Unusual infection
• HP:0002090 (1 mention) - the report calls it "recurrent fungal infection group"; HP calls it Pneumonia
• HP:0012125 (1 mention) - the report calls it "HPV-related neoplasia; or map via NCIT"; HP calls it Prostate cancer
• HP:0005506 (1 mention) - the report calls it "bone marrow hypocellularity"; HP calls it Chronic myelogenous leukemia

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

• UBERON:0000132 (2 mentions) - UBERON does not contain this term

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• MONDO:0013607 (3 mentions) - the report calls it "GATA2 deficiency"; MONDO calls it monocytopenia with susceptibility to infections, and lists "immunodeficiency 21" among its other names
• UBERON:0002371 (2 mentions) - the report calls it "UBERON suggestions: bone marrow"; UBERON calls it bone marrow**

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, MGI.